Dr. Eric Y. Mou, MD
Hematology (Hematology (Internal Medicine) Physician)
- Medicare participating
At a glance
- Medical school
- University of Iowa, Rj & L Carver College of Medicine (2014)
- Years since graduation
- 12
- In the NPI registry since
- 2014
- Medicare patients seen, 2024
- 202
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2014Medical school: University of Iowa, Rj & L Carver College of Medicine
- 2014Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology (Internal Medicine) Physician primary
IA license MD-47906 -
Medical Oncology Physician
IA license MD-47906
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- University of Iowa Hospital & Clinics Iowa City, IA
- Southeast Iowa Regional Medical Center West Burlington, IA
- University of Iowa Health Care Medical Center Down Iowa City, IA
Medical groups
- State University of Iowa (1,897 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 202
- Services billed
- 686
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 194 | 40 |
| Established patient office or other outpatient visit, 30-39 minutes | 182 | 96 |
| Established patient office or other outpatient visit, 40-54 minutes | 169 | 60 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 40 | 14 |
| Hospital discharge day management, more than 30 minutes | 22 | 22 |
| New patient office or other outpatient visit, 60-74 minutes | 19 | 19 |
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 14 | 12 |
| New patient office or other outpatient visit, 45-59 minutes | 11 | 11 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Acyclovir Other prescribers in Iowa City, IA | 105 |
| Prochlorperazine Maleate Other prescribers in Iowa City, IA | 34 |
| Ondansetron Hcl Other prescribers in Iowa City, IA | 27 |
| Valacyclovir (valacyclovir hcl) Other prescribers in Iowa City, IA | 22 |
| Sulfamethoxazole-Trimethoprim (sulfamethoxazole/trimethoprim) Other prescribers in Iowa City, IA | 22 |
| Calquence (acalabrutinib maleate) | 21 |
| Venclexta (venetoclax) | 21 |
| Prednisone Other prescribers in Iowa City, IA | 19 |
| Lenalidomide | 16 |
| Allopurinol Other prescribers in Iowa City, IA | 16 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 4 companies reported 8 payments worth $4,542 in total to this clinician.
| Acrotech Biopharma Inc. | $3,998 |
|---|---|
| Kyowa Kirin, Inc. | $261 |
| AbbVie Inc. | $238 |
| Beone Medicines USA, Inc. | $45.42 |
| Consulting Fee | $4,235 |
|---|---|
| Food and Beverage | $307 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Acrotech Biopharma Inc. Nov 14, 2025 | Consulting Fee BELEODAQ · ONCOLOGY | $3,000 |
| Acrotech Biopharma Inc. Nov 13, 2025 | Consulting Fee BELEODAQ · ONCOLOGY · in-kind | $679 |
| AbbVie Inc. May 2, 2025 | Consulting Fee VENCLEXTA · ONCOLOGY | $238 |
| Acrotech Biopharma Inc. Nov 13, 2025 | Consulting Fee BELEODAQ · ONCOLOGY · in-kind | $210 |
| Acrotech Biopharma Inc. Nov 14, 2025 | Consulting Fee BELEODAQ · ONCOLOGY · in-kind | $109 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 5 industry-funded studies in 2025, from 4 companies. The companies reported $404,424 in research payments for these studies, mostly to the institutions running them.
- A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
Beone Medicines USA, Inc. · Recruiting · NCT05006716 - Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL
Genentech, Inc. - Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL)
Beigene, Ltd. · Active, not recruiting · NCT06073821 - An openlabel phase 1 study to evaluate the safety of SGN35T in adults with advanced malignancies
Pfizer Inc. - Glofitamab ctDNA study
Genentech, Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.